Mid
N
NVAXAI Stock Diagnostic Report
Novavax expects $235M-$275M in 2026 adjusted total revenue while targeting $150M-$200M in 2028 non-GAAP R&D and SG&A
Novavax has presented its revenue and expense targets for 2026 and 2028, along with a capital-efficient operating model and a partnership-focused strategy.
View Source Article ↗AI CATALYST SCORE75 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time